Chemotherapy-colchicine interaction in a child with Familial Mediterranean Fever and Hodgkin Lymphoma

Karin Petra Sabine Langenberg-Ververgaert, Ronald M. Laxer, Angela S. Punnett, Lee L Dupuis, Yaron Finkelstein, Oussama Abla
  • Karin Petra Sabine Langenberg-Ververgaert
    Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada., Canada | karin.langenberg@sickkids.ca
  • Ronald M. Laxer
    Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.,
  • Angela S. Punnett
    Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.,
  • Lee L Dupuis
    Department of Pharmacy, The Hospital for Sick Children, Toronto, Canada. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada. Research Institute, The Hospital for Sick Children, Toronto, Canada., Canada
  • Yaron Finkelstein
    The Hospital for Sick Children, University of Toronto, Toronto, Canada., Canada
  • Oussama Abla
    Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.,

Abstract

Familial Mediterranean Fever (FMF) has been associated with hematological malignancies, but has not been reported in association with Hodgkin lymphoma (HL). We hereby describe the first pediatric patient with FMF and stage IIA nodular sclerosis HL. She was treated with prednisone, doxorubicin, vincristine and etoposide (OEPA). However, she suffered more than expected treatment-related toxicity due to interaction with colchicine. Colchicine had to be discontinued during her second cycle of chemotherapy which was well tolerated. She is currently in remission at 17 months after her HL diagnosis, and her FMF is under control with colchicine without any signs of toxicity.

Keywords

Hodgkin lymphoma, familial Mediterranean fever, colchicine

Full Text:

PDF
HTML
Submitted: 2017-12-06 23:47:29
Published: 2018-03-01 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar

References

Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103.

Lee JH, Kim Y, Choi JW, Kim YS. Prevalence and prognostic significance of Epstein-Barr virus infection in classical Hodgkin's lymphoma: a meta-analysis. Arch Med Res. 2014 Jul;45(5):417-31

Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. Blood Rev. 2008 Sep;22(5):261-81.

Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rösen-Wolff A, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 2001 Jul 1;98(1):194-200

Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972. Dec 21;287(25):1302.

Alghamdi M. Familial Mediterranean fever, review of the literature. Clin Rheumatol. 2017 Aug;36(8):1707-1713.

Oktenli C, Sayan O, Celik S, Erikci AA, Tunca Y, Terekeci HM, et al. High frequency of MEFV gene mutations in patients with myeloid neoplasm. Int J Hematol. 2010 Jun;91(5):758-61.

Celik S, Tangi F, Oktenli C. Increased frequency of Mediterranean fever gene variants in multiple myeloma. Oncol Lett. 2014 Oct;8(4):1735-1738. Epub 2014 Aug 4.

Sayan O, Kilicaslan E, Celik S, Tangi F, Erikci AA, Ipcioglu O, et al. High Frequency of Inherited Variants in the MEFV Gene in Acute Lymphocytic Leukemia. Indian J Hematol Blood Transfus. 2011 Sep;27(3):164-8.

Oktenli C, Celik S. High frequency of inherited variants in the MEFV gene in patients with hematologic neoplasms: a genetic susceptibility? Int J Hematol. 2012 Apr;95(4):380-5.

Celik S, Oktenli C, Kilicaslan E, Tangi F, Sayan O, Ozari HO, et al. Frequency of inherited variants in the MEFV gene in myelodysplastic syndrome and acute myeloid leukemia. Int J Hematol. 2012 Mar;95(3):285-90.

Celik S, Erikci AA, Tunca Y, Sayan O, Terekeci HM, Umur EE, et al. The rate of MEFV gene mutations in hematolymphoid neoplasms. Int J Immunogenet. 2010 Oct;37(5):387-91.

Dorffel W, Luders H, Ruhl U: Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin’s disease in children and adolescents: Analysis and outlook. Klin Padiatr 215:139-145, 2003

Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997 Oct;40(10):1879-85.

Yalçinkaya F, Ozen S, Ozçakar ZB, Aktay N, Cakar N, Düzova A, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009 Apr;48(4):395-8.

Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol. 2009; 27:621-68.

Yilmaz, E., Ozen, S., Balci, B., Duzova, A., Topaloglu, R., Besbas, et al. Mutation frequency of familial Mediterranean fever and evidence for a high carrier rate in the Turkish population. Europ. J. Hum. Genet. 9: 553-555, 2001.

Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986 Apr 17;314(16):1001-5.

Lu Y, Chen J, Xiao M, Li W, Miller DD. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res. 2012 Nov;29(11):2943-71.

Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010 Jun;48(5):407-14.

Abstract views:
414

Views:
PDF
45
HTML
127

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2018 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185     •     Privacy